Investment Banking
Joint Bookrunner on Olema Oncology’s $218.5MM CMPO
November 24, 2025
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Olema Oncology’s $218.5MM Confidentially Marketed Public Offering
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Olema from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $218.5MM.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Healthcare Equity Capital Markets
Name:
Andy Linderman
Title:Managing Director, Healthcare Capital Markets Investment Banking
Name:
James Yoo
Title:Managing Director, Healthcare Capital Markets Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC. 8623288.1